Dermal Filler Clinical Trial
Official title:
An Interventional, Pre-Market, Double-Blinded, Controlled, Two Stages Study to Evaluate the Safety and Performance of Crosslinked Hyaluronic Acid Hydrogel (With and Without Lidocaine) for the Treatment of Soft Tissue Deficits
The aim of this interventional, pre-market, double- blinded, controlled, two stages study is to evaluate the performance and safety of Crosslinked Hyaluronic Acid (CLHA) Hydrogel (with and without Lidocaine) for the Treatment of Soft Tissue Deficits.
The performance of Crosslinked Hyaluronic Acid Hydrogel (with and without Lidocaine), for the correction of congenital and acquired deficits of soft tissue, will be evaluated using the change from baseline to V3 in the Wrinkle Severity Rating Scale (WSRS) for 26 mg/ml and 18mg/ml CLHA formulations and in the Lip Fullness Scale (LFS) for 20 mg/ml CLHA formulation. The duration of the aesthetic effect of Crosslinked Hyaluronic Acid Hydrogel (with and without Lidocaine) for the correction of NLFs, perioral wrinkles and lips augmentation, will be assessed using the mean of the absolute change from baseline to each follow up visit in WSRS and LFS score. WSRS and LFS will be assessed by the evaluating investigator who will be different by the treating investigator. The aesthetic appearance of the Crosslinked Hyaluronic Acid Hydrogel (with and without Lidocaine) will be assessed using the Global Aesthetic Improvement Scale (GAIS) at each visit. The GAIS will be completed by both the subjects and the evaluating investigators; The volume of material required to achieve an optimal correction result will be assessed at baseline and at optional touch up; The pain intensity after injection of Crosslinked Hyaluronic Acid Hydrogel (with and without Lidocaine) will be assessed using a Numerical Rating Scale (NRS) 2 hours after the injection; The patient satisfaction and the usability of Crosslinked Hyaluronic Acid Hydrogel (with and without Lidocaine) will be evaluated with a specific questionnaire, completed by the Principal Investigator. The Safety of Crosslinked Hyaluronic Acid Hydrogel (with and without Lidocaine) will be assessed by facial examination and vital signs over the duration of the study. Adverse events and serious adverse events will be collected at each planned visit into a diary dispensed to patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546516 -
Safety and Efficacy of the HA-based Dermal Fillers HYAcorp Lips and Face
|
||
Completed |
NCT04546152 -
Safety and Efficacy of the HA-based Dermal Fillers HYAPROF® SOFT and HYAPROF® BALANCE
|
||
Active, not recruiting |
NCT05694286 -
A Prospective Evaluation of Infraorbital Filler Injection
|
N/A | |
Completed |
NCT02654522 -
The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers
|
Phase 1 | |
Completed |
NCT05822778 -
Formaderm (Hyaluronic Acid) for Facial Soft Tissue Augmentation
|
N/A | |
Completed |
NCT05294562 -
China Post-Market Clinical Follow-up of FACILLE®
|
||
Completed |
NCT04569045 -
Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds
|
N/A | |
Completed |
NCT04622085 -
The Evaluation of the Safety and Effectiveness of ANIMERS Chiara LA and JUVÉDERM VOLUMA® for Aging Mid-Face
|
N/A | |
Completed |
NCT04599335 -
The Evaluation of the Safety and Effectiveness of a Novel Gel-type Sodium Hyaluronate for the Correction of Aging Mid-face
|
N/A |